The Pareto Optimization of Cure: A Primary Bivariate Copula Meta-Analysis Solving the Graft-Versus-Leukemia Paradox in Acute Myeloid Leukemia

Faiza Khalid[1], Laiba Manzoor[2], Haroon Alamy[3], Raj Nandan Chennuri[4], Shaiza Maryam[5], Sravani Bhavanam[6], Iman Khan[7], Hrishikesh Kommu[8], Ashesh Das[9]

[1] Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan
[2] Dow University of Health Sciences, Karachi, Pakistan
[3] Desert Regional Medical Center, Palm Springs, CA, USA
[4] New York Medical College/Saint Clare's and St Mary's Hospitals, Denville, NJ, USA
[5] Shifa International Hospital, Islamabad, Pakistan
[6] Brookdale University Hospital and Medical Center, New York, NY, USA
[7] Ziauddin Medical University, Karachi, Pakistan
[8] JIPMER, Puducherry, India
[9] KPC medical College and hospital Kolkata india

Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) presents a fundamental therapeutic paradox: myeloablative conditioning (MAC) reduces relapse but increases non-relapse mortality (NRM), while reduced -intensity conditioning (RIC) lowers NRM but permits higher relapse. This graft-versus-leukemia (GVL) trade-off has never been formally optimized. We hypothesized that bivariate copula modeling of competing risks could quantify the dependence structure between relapse and NRM, enabling Pareto optimization to identify regimens that simultaneously minimize both endpoints.

Methods

We conducted a meta-analysis synthesizing data from four databases (Google Scholar, PubMed, Cochrane) encompassing 99 unique studies of MAC, RIC, venetoclax-augmented conditioning (MAC+Ven, RIC+Ven), and haploidentical transplantation (Haplo-SCT) in AML. Individual patient data (N=2,000; 400 per arm) were reconstructed using competing-risks simulation calibrated to published benchmarks. Two-year cumulative incidence functions (CIFs) were estimated via Aalen-Johansen methods. Clayton and Gaussian copulas were fitted via maximum likelihood with 1,000-iteration bootstrap confidence intervals. Pareto frontiers were constructed in relapse-NRM space, and Euclidean distance to the utopia point (0% relapse, 0% NRM) identified optimal regimens.

Results

Two-year CIFs revealed marked heterogeneity: MAC (relapse 27.8%, NRM 23.5%), RIC (relapse 42.5%, NRM 11.8%), MAC+Ven (relapse 17.3%, NRM 26.3%), RIC+Ven (relapse 37.0%, NRM 13.8%), and Haplo-SCT (relapse 27.3%, NRM 30.8%). Clayton copula dependence parameters (θ) demonstrated strong positive dependence in MAC (θ=3.725, 95% CI 2.837–4.927), MAC+Ven (θ=3.453, 95% CI 3.064–3.742), and Haplo-SCT (θ=10.000, 95% CI 7.811–10.000), but weak dependence in RIC (θ=0.493, 95% CI 0.402–0.575) and RIC+Ven (θ=0.734, 95% CI 0.671–0.782). Gaussian copula correlations paralleled these findings (MAC ρ=0.958, RIC ρ=0.571, MAC+Ven ρ=0.943, RIC+Ven ρ=0.668, Haplo-SCT ρ=0.990). Pareto frontier analysis identified MAC+Ven as closest to the utopia point with the highest overall survival proxy (56.5%), while Haplo-SCT was Pareto-dominated.

Conclusion

Bivariate copula meta-analysis reveals that MAC +venetoclax achieves Pareto-optimal balance in the GVL paradox, offering superior disease control (17.3% relapse) despite modestly elevated NRM (26.3%) and yielding the highest overall survival proxy (56.5%). The strong positive dependence (θ=3.453, ρ=0.943) between relapse and NRM in MAC+Ven suggests shared biological mechanisms amenable to targeted intervention. This copula-based framework provides the first quantitative solution to transplant conditioning optimization in AML.